<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644620304323</prism:url><dc:identifier>doi:10.1016/j.drudis.2020.10.015</dc:identifier><eid>1-s2.0-S1359644620304323</eid><prism:doi>10.1016/j.drudis.2020.10.015</prism:doi><pii>S1359-6446(20)30432-3</pii><dc:title>The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>26</prism:volume><prism:issueIdentifier>1</prism:issueidentifier><prism:startingPage>218</prism:startingpage><prism:endingPage>228</prism:endingpage><prism:pageRange>218-228</prism:pagerange><prism:number>1</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2021-01-31</prism:coverdate><prism:coverDisplayDate>January 2021</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Caston, Rachel A.</dc:creator><dc:creator>Gampala, Silpa</dc:creator><dc:creator>Armstrong, Lee</dc:creator><dc:creator>Messmann, Richard A.</dc:creator><dc:creator>Fishel, Melissa L.</dc:creator><dc:creator>Kelley, Mark R.</dc:creator><dc:description>
                  Apurinic/apyrimidinic (AP) endonuclease–reduction/oxidation factor 1 (APE1/Ref-1, also called APE1) is a multifunctional enzyme with crucial roles in DNA repair and reduction/oxidation (redox) signaling. APE1 was originally described as an endonuclease in the Base Excision Repair (BER) pathway. Further study revealed it to be a redox signaling hub regulating critical transcription factors (TFs). Although a significant amount of focus has been on the role of APE1 in cancer, recent findings support APE1 as a target in other indications, including ocular diseases [diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD)], inflammatory bowel disease (IBD) and others, where APE1 regulation of crucial TFs impacts important pathways in these diseases. The central responsibilities of APE1 in DNA repair and redox signaling make it an attractive therapeutic target for cancer and other diseases.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644620304323" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644620304323" rel="scidir"/></link></coredata><objects><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="847" size="118082">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="425" size="62627">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="164" size="7122">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="111" size="6176">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="3750" size="942798">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1884" size="482646">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1155701">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620304323-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85095724096</scopus-id><scopus-eid>2-s2.0-85095724096</scopus-eid><pubmed-id>33148489</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85095724096" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20201024">2020-10-24</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20201024">2020-10-24</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210123">2021-01-23</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210123">2021-01-23</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-01-23T12:52:44</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644620304323</xocs:eid>
      <xocs:pii-formatted>S1359-6446(20)30432-3</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644620304323</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2020.10.015</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644621X00025</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210309">2021-03-09T22:24:03.607392Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210101</xocs:date-search-begin>
      <xocs:date-search-end>20210131</xocs:date-search-end>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1603504421">2020-10-24T01:53:41.912433Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authlast footnotes grantnumber grantsponsor highlightsabst orcid primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>26</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>26</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>1</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>1</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 26, Issue 1</xocs:vol-iss-suppl-text>
      <xocs:sort-order>22</xocs:sort-order>
      <xocs:first-fp>218</xocs:first-fp>
      <xocs:last-lp>228</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>218</xocs:first-page>
         <xocs:last-page>228</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202101</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>January 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-01-01</xocs:cover-date-start>
      <xocs:cover-date-end>2021-01-31</xocs:cover-date-end>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Post Screen</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>MULTIFUNCTIONALAPE1DNAREPAIRREDOXSIGNALINGPROTEINADRUGTARGETINHUMANDISEASE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>CASTON</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>R</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>APE1 in DNA repair</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>APE1 in redox signaling</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Additional functions of APE1</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>RNA processing</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Role of APE1 in mitochondria and metabolism</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Nucleophosmin/nucleoplasmin and APE1 interaction</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>APE1 as a therapeutic opportunity for various cancers</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Overexpression</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Functional significance</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Polymorphisms</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>The contribution of APE1 also extends to other disease pathologies</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Inhibitors of APE1 DNA repair or redox signaling</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>APE1 DNA repair function inhibitors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>APE1 redox inhibitors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Clinical trials</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Future directions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>SHAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>WALLACE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>14</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>ISHCHENKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2564</xocs:ref-first-fp>
            <xocs:ref-last-lp>2569</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>WHITAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>399</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>GROS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>73</xocs:ref-first-fp>
            <xocs:ref-last-lp>81</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>LUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>695</xocs:ref-first-fp>
            <xocs:ref-last-lp>705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>LOGSDON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2722</xocs:ref-first-fp>
            <xocs:ref-last-lp>2732</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>FISHEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1698</xocs:ref-first-fp>
            <xocs:ref-last-lp>1708</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>YAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>15158</xocs:ref-first-fp>
            <xocs:ref-last-lp>15171</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>581</xocs:ref-first-fp>
            <xocs:ref-last-lp>588</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>WURTMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>34</xocs:ref-first-fp>
            <xocs:ref-last-lp>49</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>ANTONIALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>797</xocs:ref-first-fp>
            <xocs:ref-last-lp>815</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>12</xocs:ref-first-fp>
            <xocs:ref-last-lp>25</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>TELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>366</xocs:ref-first-fp>
            <xocs:ref-last-lp>371</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>GAROFALO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>27</xocs:ref-first-fp>
            <xocs:ref-last-lp>33</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>CHATTOPADHYAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2067</xocs:ref-first-fp>
            <xocs:ref-last-lp>2076</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>BARCHIESI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>5451</xocs:ref-first-fp>
            <xocs:ref-last-lp>5464</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>CODRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>102675</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>HEATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>807</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>BOX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>POLETTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1641</xocs:ref-first-fp>
            <xocs:ref-last-lp>1652</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>COLOMBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2595</xocs:ref-first-fp>
            <xocs:ref-last-lp>2609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>BANUELOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2254</xocs:ref-first-fp>
            <xocs:ref-last-lp>2259</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>CHIARELLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3228</xocs:ref-first-fp>
            <xocs:ref-last-lp>3239</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>MALFATTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>LOGSDON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>13759</xocs:ref-first-fp>
            <xocs:ref-last-lp>13773</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4406</xocs:ref-first-fp>
            <xocs:ref-last-lp>4419</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>9</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>MCILWAIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>10962</xocs:ref-first-fp>
            <xocs:ref-last-lp>10977</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>COCCHIOLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1815</xocs:ref-first-fp>
            <xocs:ref-last-lp>1832</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>4426</xocs:ref-first-fp>
            <xocs:ref-last-lp>4438</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>FISHEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1947</xocs:ref-first-fp>
            <xocs:ref-last-lp>1960</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>7276502</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>S30</xocs:ref-first-fp>
            <xocs:ref-last-lp>S37</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>SHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>823</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5664</xocs:ref-first-fp>
            <xocs:ref-last-lp>5677</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>MADLENER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>17844</xocs:ref-first-fp>
            <xocs:ref-last-lp>17849</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>859</xocs:ref-first-fp>
            <xocs:ref-last-lp>866</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>PASCUT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>394</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>DING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1401</xocs:ref-first-fp>
            <xocs:ref-last-lp>1411</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>CHOLIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1307</xocs:ref-first-fp>
            <xocs:ref-last-lp>1326</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>BINSAMSUDDIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>283</xocs:ref-first-fp>
            <xocs:ref-last-lp>285</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>RAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1149</xocs:ref-first-fp>
            <xocs:ref-last-lp>1160</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>LIRUSSI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>26293</xocs:ref-first-fp>
            <xocs:ref-last-lp>26306</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>HADI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>3871</xocs:ref-first-fp>
            <xocs:ref-last-lp>3879</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>CHANGCLAUDE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4802</xocs:ref-first-fp>
            <xocs:ref-last-lp>4809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>CANBAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1295</xocs:ref-first-fp>
            <xocs:ref-last-lp>1302</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>505</xocs:ref-first-fp>
            <xocs:ref-last-lp>513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>8700</xocs:ref-first-fp>
            <xocs:ref-last-lp>8708</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2529</xocs:ref-first-fp>
            <xocs:ref-last-lp>2535</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>SANTOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>17333</xocs:ref-first-fp>
            <xocs:ref-last-lp>17343</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>ALMUTAIRI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>10</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>226</xocs:ref-first-fp>
            <xocs:ref-last-lp>234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>3459</xocs:ref-first-fp>
            <xocs:ref-last-lp>3469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>281</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>LUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1853</xocs:ref-first-fp>
            <xocs:ref-last-lp>1867</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>485</xocs:ref-first-fp>
            <xocs:ref-last-lp>494</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>4461</xocs:ref-first-fp>
            <xocs:ref-last-lp>4469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>SARDARPASHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>449</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>SAHAKIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>BARDIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>359</xocs:ref-first-fp>
            <xocs:ref-last-lp>365</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>LIUZZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1987</xocs:ref-pub-year>
            <xocs:ref-first-fp>3315</xocs:ref-first-fp>
            <xocs:ref-last-lp>3321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>FENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>79</xocs:ref-first-fp>
            <xocs:ref-last-lp>93</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>RAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3101</xocs:ref-first-fp>
            <xocs:ref-last-lp>3112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>TRILLES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1988</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>FISHEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>375</xocs:ref-first-fp>
            <xocs:ref-last-lp>395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0345">
            <xocs:ref-normalized-surname>LAEV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2531</xocs:ref-first-fp>
            <xocs:ref-last-lp>2544</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0350">
            <xocs:ref-normalized-surname>SHAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0355">
            <xocs:ref-normalized-surname>SHAHDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0360">
            <xocs:ref-normalized-surname>CHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0365">
            <xocs:ref-normalized-surname>NASSOUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>29389</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0370">
            <xocs:ref-normalized-surname>SHAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1711</xocs:ref-first-fp>
            <xocs:ref-last-lp>1732</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0375">
            <xocs:ref-normalized-surname>WAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>e111</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0380">
            <xocs:ref-normalized-surname>ILLUZZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>84</xocs:ref-first-fp>
            <xocs:ref-last-lp>98</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0385">
            <xocs:ref-normalized-surname>BARRETINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>603</xocs:ref-first-fp>
            <xocs:ref-last-lp>607</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0390">
            <xocs:ref-normalized-surname>REES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>109</xocs:ref-first-fp>
            <xocs:ref-last-lp>116</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0395">
            <xocs:ref-normalized-surname>WEINBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>9</xocs:ref-first-fp>
            <xocs:ref-last-lp>15</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0400">
            <xocs:ref-normalized-surname>CESARATTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1099</xocs:ref-first-fp>
            <xocs:ref-last-lp>1112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0405">
            <xocs:ref-normalized-surname>EVANS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>108</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0410">
            <xocs:ref-normalized-surname>TELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>14564</xocs:ref-first-fp>
            <xocs:ref-last-lp>14574</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0415">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1557</xocs:ref-first-fp>
            <xocs:ref-last-lp>1564</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0420">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>109</xocs:ref-first-fp>
            <xocs:ref-last-lp>117</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0425">
            <xocs:ref-normalized-surname>POLETTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>34</xocs:ref-first-fp>
            <xocs:ref-last-lp>39</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0430">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>917</xocs:ref-first-fp>
            <xocs:ref-last-lp>922</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0435">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>23383</xocs:ref-first-fp>
            <xocs:ref-last-lp>23398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0440">
            <xocs:ref-normalized-surname>ABDELFATAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>411</xocs:ref-first-fp>
            <xocs:ref-last-lp>421</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0445">
            <xocs:ref-normalized-surname>WOO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>e99528</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0450">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>524</xocs:ref-first-fp>
            <xocs:ref-last-lp>535</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0455">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0460">
            <xocs:ref-normalized-surname>KAUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>250</xocs:ref-first-fp>
            <xocs:ref-last-lp>254</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0465">
            <xocs:ref-normalized-surname>KELLEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>300</xocs:ref-first-fp>
            <xocs:ref-last-lp>309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0470">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>93</xocs:ref-first-fp>
            <xocs:ref-last-lp>100</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0475">
            <xocs:ref-normalized-surname>BAPAT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>988</xocs:ref-first-fp>
            <xocs:ref-last-lp>998</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0480">
            <xocs:ref-normalized-surname>POLETTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>688</xocs:ref-first-fp>
            <xocs:ref-last-lp>704</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0485">
            <xocs:ref-normalized-surname>MADALA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0490">
            <xocs:ref-normalized-surname>SEIPLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>669</xocs:ref-first-fp>
            <xocs:ref-last-lp>677</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0495">
            <xocs:ref-normalized-surname>ZAWAHIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>20</xocs:ref-first-fp>
            <xocs:ref-last-lp>32</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0500">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>147</xocs:ref-first-fp>
            <xocs:ref-last-lp>155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0505">
            <xocs:ref-normalized-surname>MCNEILL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>27</xocs:ref-first-fp>
            <xocs:ref-last-lp>38</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0510">
            <xocs:ref-normalized-surname>FROSSI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5198</xocs:ref-first-fp>
            <xocs:ref-last-lp>5207</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>CASTONX2021X218</xocs:refkey3>
         <xocs:refkey4lp>CASTONX2021X218X228</xocs:refkey4lp>
         <xocs:refkey4ai>CASTONX2021X218XR</xocs:refkey4ai>
         <xocs:refkey5>CASTONX2021X218X228XR</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-agreements>
            <xocs:or-agreement>
               <xocs:or-agreement-id>https://vtw.elsevier.com/content/oragreement/10130</xocs:or-agreement-id>
               <xocs:or-agreement-name>CHU_DOD</xocs:or-agreement-name>
               <xocs:or-agreement-terms>publishAcceptedManuscriptIndexable</xocs:or-agreement-terms>
            </xocs:or-agreement>
         </xocs:or-agreements>
         <xocs:or-agreement-license>http://www.elsevier.com/open-access/userlicense/1.0/</xocs:or-agreement-license>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-01-23T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
         <xocs:cp-license-lines/></xocs:cp-license-lines>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-10-22T12:39:51.421Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>DOD</xocs:funding-agency-acronym>
            <xocs:funding-agency>U.S. Department of Defense</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100000005</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>RCF</xocs:funding-agency-acronym>
            <xocs:funding-agency>Riley Children's Foundation</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100016606</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>NIH</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Institutes of Health</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100000002</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(20)30432-3</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644620304323</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644620304323</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2020.10.015</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2021-02-27T04:18:05.453996Z</xocs:timestamp>
         <xocs:cover-date-start>2021-01-01</xocs:cover-date-start>
         <xocs:cover-date-end>2021-01-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/MAIN/application/pdf/25575f5961162e99d532370201fec503/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1174516</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644620304323-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/PREVIEW/image/png/9efc936eddac294456cadc39dbc20dbf/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>100390</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr1/DOWNSAMPLED/image/jpeg/9db34c0da0f1ca008b3d729c65ff4885/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>118082</xocs:filesize>
               <xocs:pixel-height>847</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr2/DOWNSAMPLED/image/jpeg/07ca8c83e2f36dc87702f6023b172318/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>62627</xocs:filesize>
               <xocs:pixel-height>425</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr1/THUMBNAIL/image/gif/2747ce5856d6263c5ac48c7ce5b0fdc8/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7122</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr2/THUMBNAIL/image/gif/c8d9cacfc8ebe81067dc7fd438076883/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6176</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr1/HIGHRES/image/jpeg/c75f74ffd078c357b2fa385fef9d8283/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>942798</xocs:filesize>
               <xocs:pixel-height>3750</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620304323/gr2/HIGHRES/image/jpeg/a719026ac23a042a83aa44b26eec8b11/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>482646</xocs:filesize>
               <xocs:pixel-height>1884</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620304323-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1155701</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10KQWG48G49/MAIN/application/pdf/5dbe11f6f514910caf16f79e62a84f88/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.5" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2819</aid>
            <ce:pii>S1359-6446(20)30432-3</ce:pii>
            <ce:doi>10.1016/j.drudis.2020.10.015</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">Apurinic/apyrimidinic endonuclease 1 (APE1) protein regions, functions, and applications. Amino acids (AAs) indicated in <ce:bold>(a)</ce:bold> are the major AAs that are vital for the APE1 functions shown in <ce:bold>(b)</ce:bold> 
                     <ce:cross-ref id="crf0005" refid="bib0505">[102]</ce:cross-ref>. The redox signaling region spans AA 35–12,7 whereas the DNA repair region includes AA ∼65–318. Lys at position 6 and 7 affects the movement of APE1 from the nucleus to cytoplasm. Asp70 is involved in the 3′-phosphodiesterase activity of APE1, Lys98 is implicated in nucleotide incision repair (NIR), Arg 177 for base excision repair (BER) coordination, Asp210 for general nuclease function, and Phe266 for 3′ to 5′-exonuclease. Cys involved in APE1 redox activity are Cys65, 93, and 99. The mitochondrial targeting sequence has been localized to AA 289–318. Maroon color reflects regions of APE1 functions and applications involved in redox signaling; gold indicates APE1 repair functions, nuclease functions and applications; green indicates mitochondrial targeting sequences; and blue indicates potential diagnosis applications. Red indicates redox inhibitors that have either reached clinical trials (APX3330) or are in the pre-investigation new drug (IND)-enabling stage for future clinical trials <ce:cross-refs id="crfs0005" refid="bib0005 bib0505 bib0510">[1,102,103]</ce:cross-refs>. <ce:bold>(c)</ce:bold> Applications that have been related to APE1 and potential indications for therapeutics or diagnosis of a variety of diseases. <ce:bold>(d)</ce:bold> Details of the DNA BER pathway and the role of APE1. Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular edema; DR, diabetic retinopathy; IBD, irritable bowel disease.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0005" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644620304323/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">Redox signaling function of apurinic/apyrimidinic endonuclease 1 (APE1). <ce:bold>(a)</ce:bold> APE1 converts inactive, oxidized transcription factors (TFs) to active, reduced TFs through protein–protein interactions with APE1. These TFs include, but are not limited to nuclear factor (NF)-κB, hypoxia-inducible factor (HIF)-1α, signal transducer and activator of transcription 3 (STAT3), Activator protein 1 (AP-1), and cAMP-response element binding protein (CREB). APX compounds, such as APX3330, which has completed Phase I clinical trials, or next-generation compounds APX2009 and APX2014, block the ability of APE1 to perform this redox signaling activity. <ce:bold>(b)</ce:bold> Cartoon of APE1 regulation of various TFs regulated by APE1 redox signaling. Inhibition of NFκB leads to a reduction in IL-6, TNFα, and other inflammatory agents. HIF-1α inhibition leads to a reduction in the production of vascular endothelial growth factor (VEGF), carbonic anhydrase 9 (CA9), and other angiogenesis-related genes. STAT3 inhibition results in a decrease in inflammatory cytokines as well as stemness regulators. AP-1, a dimer of c-Fos and c-Jun, regulates the expression of genes involved in cell growth, differentiation, and apoptosis. Finally, CREB is a TF that has been implicated in the expression of neuropeptides and genes involved in neuronal plasticity <ce:cross-ref id="crf0010" refid="bib0005">[1]</ce:cross-ref>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0010" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644620304323/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">APE1 redox-controlled TFs</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0015" role="short">Table 1</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TF</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Function</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Type of cancer regulated by APE1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">AP-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Proliferation, differentiation, apoptosis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic, BC, CRC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0015" refid="bib0005">[1]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">ATF</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Stress response</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>In vitro</italic>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0020" refid="bib0005">[1]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">c-Myb</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cell cycle regulation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>In vitro</italic>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0025" refid="bib0005">[1]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">CREB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Neuroplasticity, memory formation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>In vitro</italic>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0030" refid="bib0005">[1]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Egr-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Differentiation, mitogenesis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bone, colon, HeLa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0035" refid="bib0400">[80]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">HIF-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Glycolysis, angiogenesis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0010" refid="bib0035 bib0040">[7,8]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">NFκB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Proliferation, migration, invasion</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic, BCa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0040" refid="bib0040">[8]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">NY-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chromatin accessibility, transcription start site selection</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HeLa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0045" refid="bib0405">[81]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">P53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA repair, cell-cycle arrest, apoptosis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon, liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0015" refid="bib0005 bib0090">[1,18]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PAX5/8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Differentiation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lymphocyte</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0050" refid="bib0405">[81]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PEBP2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hematopoiesis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>In vitro</italic>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0055" refid="bib0405">[81]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PTEN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cell-cycle regulation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bone, colon, HeLa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0060" refid="bib0400">[80]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Proliferation, invasion, immunosuppression</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic, liver, BCa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0065" refid="bib0005">[1]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">TTF-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Thyroid and lung gene activation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HeLa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0070" refid="bib0410">[82]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0010" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Role of APE1 in cancers<ce:cross-ref id="crf0075" refid="tblfn0005">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0020" role="short">Table 2</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer type</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">APE1 contribution</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PDAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression: chemoresistance, radioresistance<br/></br>Redox function: chemoresistance, angiogenesis<br/></br>Repair function: gemcitabine resistance</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0020" refid="bib0130 bib0160 bib0005">[26,32,1]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">BCa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Urinary levels as diagnostic marker<br/></br>High serum levels</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0080" refid="bib0160">[32]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">CRC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Redox function: chemoresistance<br/></br>Asp148 Glu polymorphism increases risk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0025" refid="bib0090 bib0415">[18,83]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Loss of stability causes apoptosis<br/></br>Redox function<br/></br>Endonuclease activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0085" refid="bib0200">[40]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">MPNST</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression: redox function</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0090" refid="bib0350">[70]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Lung</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression and chemoresistance<br/></br>Ile64Val and Asp148Glu promoter variants increase risk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0030" refid="bib0135 bib0415">[27,83]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">BC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Asp148Glu polymorphism protects against acute adverse effects after radiotherapy<br/></br>Asp148Glu polymorphism might contribute to ionizing radiation hypersensitivity and cancer susceptibility<br/></br>Hyperacetylation resulting in secretion causes apoptosis in TNBC [low expression might select for aggressive ER-positive cancers; high expression in Luminal A subtype (ER positive)<cross-ref id="crf0095" refid="tblfn0010">
                              <sup loc="post">b</sup>
                           </cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0035" refid="bib0230 bib0420 bib0425 bib0430 bib0435 bib0440 bib0445">[46,84–89]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PCa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Redox function<br/></br>Asp148Glu polymorphism contributes to increased cancer risk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0040" refid="bib0150 bib0160">[30,32]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Subcellular localization contributes to cancer properties<br/></br>Secretion into serum enhances inflammatory response</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0100" refid="bib0195">[39]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">EAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Repair function protects against acidic bile salts (ABS)-induced DNA damage<br/></br>Redox function via EGFR–STAT3 axis, COX2/VEGF regulation, and activation of NFκB-p65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0105" refid="bib0155">[31]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Cervical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Cytoplasmic overexpression: radioresistance</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0110" refid="bib0450">[90]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Head and neck</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Nuclear localization protects HNSCCs from oxidative stress, thus evading death<br/></br>Asp148Glu polymorphism associated with smoking and/or tobacco chewing increases risk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0115" refid="bib0415">[83]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Oral</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression and high serum levels<br/></br>Asp148Glu polymorphism associated with malignant transformation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0045" refid="bib0415 bib0190">[83,38]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">GBM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Repair activity: chemoresistance<br/></br>Redox function: resistance to TMZ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0120" refid="bib0205">[41]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Ovarian</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression and chemoresistance<br/></br>Cytoplasmic localization associated with tumor progression and low survival<br/></br>Interaction with NPM1 through BER and rRNA activities enhances cancer aggressiveness<br/></br>Redox function</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0160">[32]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Osteosarcoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Cytoplasmic Overexpression – Platin Resistance<br/></br>Induces angiogenesis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0130" refid="bib0455">[92]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overexpression<br/></br>Overexpression in MiTF-positive melanoma cells<br/></br>Repair activity inhibition targets melanoma<br/></br>Loss of APE1 through Wnt antagonist, sFRP2, renders melanoma sensitive to vemurafenib resistance</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0135" refid="bib0460">[93]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tblfn0005">
                  <ce:label>a</ce:label>
                  <ce:note-para id="npar0005" view="all">Abbreviations: ER, estrogen receptor; HNSCC, head and neck squamous cell carcinoma; MiTF, melanocyte inducing transcription factor; sFRP2, secreted frizzled related protein 2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0010">
                  <ce:label>b</ce:label>
                  <ce:note-para id="npar0010" view="all">Contradictory results.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0015" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0025" view="all">Inhibitors of APE1 DNA repair and redox signaling</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0025" role="short">Table 3</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Function inhibited</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">3-Benzylcarbamoyl-2-methoxybenzoic acid inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0140" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">5-(Hydroxymethyl)-2-furfural,</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Antioxidant</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0145" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">6-Hydroxy-dl-DOPA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0150" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">9-Aminoellipticine aminoellipticine 1, isopropyl-oxazolopyridocarbazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0155" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">AJAY -1, -2, -3, -4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0160" refid="bib0325">[65]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">APE1-endonuclease inhibitor (Compound 3)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0165" refid="bib0330">[66]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">APX2007, APX2009, APX2014, APX2032</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Redox</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0050" refid="bib0300 bib0465">[60,94]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">APX3330</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Redox</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0055" refid="bib0005 bib0355 bib0470">[1,71,95]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">ARO1, ARO3, ARO6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0170" refid="bib0475">[96]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">AT-101</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0175" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Aurintricarboxylic acid inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0180" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Bis-naphthalene macrocycles</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0185" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">CRT0044876</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0190" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Fiduxosin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0195" refid="bib0480">[97]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Heterodimeric compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0200" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Hycanthone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0205" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Lucanthone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0210" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">MC043, MC047, MC042, and MC018</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0215" refid="bib0335">[67]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Methoxyamine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0220" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Methyl-3,4-dephostatin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0225" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">MGAP-9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0230" refid="bib0485">[98]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Mitoxantrone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0235" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">MLS001196838, MLS000587064, MLS000737267, and MLS000090966</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0240" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Myricetin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0245" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <italic>N</italic>-(3-(Benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0250" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">NCI-13,755, NCI-13793</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0255" refid="bib0490">[99]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Pharmacophore model inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0260" refid="bib0495">[100]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">PNRI-299</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Weak redox</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0265" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Reactive Blue 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0270" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">SB206553</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mild repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0275" refid="bib0480">[97]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Spiclomazine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0280" refid="bib0480">[97]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Tanshinone IIA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Weak redox</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0285" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Thiolactomycin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0290" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Troglitazone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mild repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0295" refid="bib0480">[97]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Tyrphostin AG 538</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0300" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Zinc69565400/related compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Repair</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0305" refid="bib0500">[101]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Post-screen</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" author-id="S1359644620304323-e5e7be996d8dbbd9f4c1fbb601514dfb">
                  <ce:given-name>Rachel A.</ce:given-name>
                  <ce:surname>Caston</ce:surname>
                  <ce:cross-ref id="crf0310" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0315" refid="fn0005">
                     <ce:sup loc="post">‡</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0010" orcid="0000-0001-9928-3941" author-id="S1359644620304323-8e4be66a41eed5768936b3b40e62ed0d">
                  <ce:given-name>Silpa</ce:given-name>
                  <ce:surname>Gampala</ce:surname>
                  <ce:cross-ref id="crf0320" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0325" refid="fn0005">
                     <ce:sup loc="post">‡</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0015" author-id="S1359644620304323-aa617f3c62c3847c6bd9816b1155fa26">
                  <ce:given-name>Lee</ce:given-name>
                  <ce:surname>Armstrong</ce:surname>
                  <ce:cross-ref id="crf0330" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0020" orcid="0000-0002-2112-0277" author-id="S1359644620304323-bcea4a4cdc5050234a99e1af7edef107">
                  <ce:given-name>Richard A.</ce:given-name>
                  <ce:surname>Messmann</ce:surname>
                  <ce:cross-ref id="crf0335" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0025" orcid="0000-0002-9436-6382" author-id="S1359644620304323-bbad34c732445c7f43dc9505ce7e00a6">
                  <ce:given-name>Melissa L.</ce:given-name>
                  <ce:surname>Fishel</ce:surname>
                  <ce:cross-ref id="crf0340" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0345" refid="aff0015">
                     <ce:sup loc="post">3</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0350" refid="aff0020">
                     <ce:sup loc="post">4</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0355" refid="aff0025">
                     <ce:sup loc="post">5</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0030" orcid="0000-0001-9472-1826" author-id="S1359644620304323-2fa47bb66d13ec514edf3672d1641947">
                  <ce:given-name>Mark R.</ce:given-name>
                  <ce:surname>Kelley</ce:surname>
                  <ce:cross-ref id="crf0360" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0365" refid="aff0015">
                     <ce:sup loc="post">3</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0370" refid="aff0020">
                     <ce:sup loc="post">4</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0375" refid="aff0025">
                     <ce:sup loc="post">5</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0380" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644620304323-f50b42759c951be8cbf62ef4db5c3b7e">
                  <ce:label>1</ce:label>
                  <ce:textfn>Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Herman B. Wells Center for Pediatric Research</sa:organization>
                     <sa:organization>Department of Pediatrics</sa:organization>
                     <sa:organization>Indiana University School of Medicine</sa:organization>
                     <sa:address-line>1044 W. Walnut</sa:address-line>
                     <sa:city>Indianapolis</sa:city>
                     <sa:state>IN</sa:state>
                     <sa:postal-code>46202</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0010" affiliation-id="S1359644620304323-069023f3458dc9ac99431a12e8a2451d">
                  <ce:label>2</ce:label>
                  <ce:textfn>Apexian Pharmaceuticals, 20 N Meridian St, Indianapolis, IN 46204, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Apexian Pharmaceuticals</sa:organization>
                     <sa:address-line>20 N Meridian St</sa:address-line>
                     <sa:city>Indianapolis</sa:city>
                     <sa:state>IN</sa:state>
                     <sa:postal-code>46204</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0015" affiliation-id="S1359644620304323-e5058263019b4fdeb4f873f6f05ea5de">
                  <ce:label>3</ce:label>
                  <ce:textfn>Department of Pharmacology and Toxicology, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pharmacology and Toxicology</sa:organization>
                     <sa:organization>Indiana University School of Medicine</sa:organization>
                     <sa:address-line>1044 W. Walnut</sa:address-line>
                     <sa:city>Indianapolis</sa:city>
                     <sa:state>IN</sa:state>
                     <sa:postal-code>46202</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0020" affiliation-id="S1359644620304323-b703ec7f9f66946371b0dc1c722d390d">
                  <ce:label>4</ce:label>
                  <ce:textfn>Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Biochemistry and Molecular Biology</sa:organization>
                     <sa:organization>Indiana University School of Medicine</sa:organization>
                     <sa:address-line>1044 W. Walnut</sa:address-line>
                     <sa:city>Indianapolis</sa:city>
                     <sa:state>IN</sa:state>
                     <sa:postal-code>46202</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0025" affiliation-id="S1359644620304323-8da0121f13f3cccb5fb97b43b55b1e89">
                  <ce:label>5</ce:label>
                  <ce:textfn>Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Indiana University Simon Comprehensive Cancer Center</sa:organization>
                     <sa:organization>Indiana University School of Medicine</sa:organization>
                     <sa:address-line>1044 W. Walnut</sa:address-line>
                     <sa:city>Indianapolis</sa:city>
                     <sa:state>IN</sa:state>
                     <sa:postal-code>46202</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>Corresponding author:</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn0005">
                  <ce:label>‡</ce:label>
                  <ce:note-para id="npar0015" view="all">Co-first authors.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            
            <ce:abstract id="abs0010" view="all" class="author"><ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0035" view="all">Apurinic/apyrimidinic (AP) endonuclease–reduction/oxidation factor 1 (APE1/Ref-1, also called APE1) is a multifunctional enzyme with crucial roles in DNA repair and reduction/oxidation (redox) signaling. APE1 was originally described as an endonuclease in the Base Excision Repair (BER) pathway. Further study revealed it to be a redox signaling hub regulating critical transcription factors (TFs). Although a significant amount of focus has been on the role of APE1 in cancer, recent findings support APE1 as a target in other indications, including ocular diseases [diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD)], inflammatory bowel disease (IBD) and others, where APE1 regulation of crucial TFs impacts important pathways in these diseases. The central responsibilities of APE1 in DNA repair and redox signaling make it an attractive therapeutic target for cancer and other diseases.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0010">Introduction</ce:section-title>
                  <ce:para id="par0030" view="all">APE1/Ref-1 (also called APE1) is a multifunctional enzyme with crucial roles in DNA repair and reduction/oxidation (redox) signaling. APE1 was originally described as an endonuclease in the BER pathway as reviewed elsewhere <ce:cross-ref id="crf0385" refid="bib0005">[1]</ce:cross-ref>. Further study revealed APE1 to be a redox signaling hub that regulated TFs <ce:cross-ref id="crf0390" refid="bib0005">[1]</ce:cross-ref>. The central responsibilities of APE1 in DNA repair and redox signaling make it an attractive therapeutic target for cancer and other diseases (<ce:cross-ref id="crf0395" refid="fig0005">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig0005"/></ce:float-anchor>).</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0015">APE1 in DNA repair</ce:section-title>
                  <ce:para id="par0035" view="all">The functions of APE1 within the BER pathway include repair of nondistorting DNA lesions, such as oxidized, alkylated, and deaminated bases. The BER pathway comprises two branches: short- and long-patch BER <ce:cross-ref id="crf0400" refid="bib0010">[2]</ce:cross-ref> (<ce:cross-ref id="crf0405" refid="fig0005">Fig. 1</ce:cross-ref>). The endonuclease function of APE1 is essential for both branches of BER. During BER, a glycosylase first removes the lesioned base by cleaving its <ce:italic>N</ce:italic>-glycosidic bond, leaving an apurinic/apyrimidinic site (AP) site. APE1 then nicks the phosphodiester backbone of the DNA to create a 3′-hydroxyl group termini and a 5′-deoxyribose moiety, allowing a DNA polymerase to enter the DNA helix and incorporate one or more nucleotides. A ligase completes the repair.</ce:para>
                  <ce:para id="par0040" view="all">APE1 is also a part of nucleotide incision repair (NIR), a glycosylase-independent pathway <ce:cross-ref id="crf0410" refid="bib0015">[3]</ce:cross-ref>. In NIR, an endonuclease incises at a damage base site, allowing DNA synthesis to begin. This incision is the initial step in NIR, rather than an abasic site or an incision, as in BER. APE1 is reported to recognize and incise at particular base damages, specifically 5,6-dihydro-2′-deoxyuridine (DHU), 5,6-dihydrothymidine (DHT), 5-hydroxy-2-deoxyuridine (5OHU), and α-2′-deoxynucleotide. These incisions generate single-strand break ends with a 3′-hydroxyl and a 5′-dangling modified nucleotide <ce:cross-ref id="crf0415" refid="bib0020">[4]</ce:cross-ref>. The active site of endonuclease activity is the same for BER and NIR <ce:cross-ref id="crf0420" refid="bib0025">[5]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0020">APE1 in redox signaling</ce:section-title>
                  <ce:para id="par0045" view="all">The redox function of APE1 is unique to mammals <ce:cross-ref id="crf0425" refid="bib0005">[1]</ce:cross-ref>. APE1 redox signaling is a controlled process that directs the activity of diverse TFs, which subsequently affect gene expression and protein production (<ce:cross-ref id="crf0430" refid="fig0010">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig0010"/></ce:float-anchor>). The redox function of APE1 depends primarily on a buried cystine residue, Cys65, which lies within its N-terminal tail and is independent from the DNA repair portion of APE1 (<ce:cross-ref id="crf0435" refid="fig0005">Fig. 1</ce:cross-ref>) <ce:cross-ref id="crf0440" refid="bib0005">[1]</ce:cross-ref>. Cys93 and Cys99 are also implicated in the redox function of APE1 <ce:cross-ref id="crf0445" refid="bib0030">[6]</ce:cross-ref>. It is necessary for APE1 to be in a reduced state to activate TFs. APE1 reduction occurs through a thiol/sulfide exchange with thioredoxin. Once reduced, activated TFs bind to DNA <ce:cross-ref id="crf0450" refid="bib0005">[1]</ce:cross-ref>. TFs regulated by APE1 include signal transducer and activator of transcription 3 (STAT3), Activator protein 1 (AP-1), hypoxia-inducible factor (HIF)-1α, p53, nuclear factor (NF)κB, and others (<ce:cross-ref id="crf0455" refid="tbl0005">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0005"/></ce:float-anchor>). These TFs are involved in many cellular processes, including growth, inflammation, and angiogenesis <ce:cross-refs id="crfs0060" refid="bib0035 bib0040">[7,8]</ce:cross-refs>. APE1 overexpression alters its regulation of TFs as well as their downstream effectors, which, clinically, can include tumorigenic transformation, migration, and drug resistance <ce:cross-ref id="crf0460" refid="bib0035">[7]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="sect0025">Additional functions of APE1</ce:section-title>
                  <ce:section id="sec0025" view="all">
                     <ce:section-title id="sect0030">RNA processing</ce:section-title>
                     <ce:para id="par0050" view="all">RNA, as well as DNA, can become damaged <ce:cross-ref id="crf0465" refid="bib0045">[9]</ce:cross-ref>. In fact, RNA is more susceptible to base oxidation than is DNA because its bases are not protected by hydrogen bonding <ce:cross-ref id="crf0470" refid="bib0050">[10]</ce:cross-ref>. Damaged mRNA can lead to defective or mutant proteins. Oxidized and abasic RNAs have inhibitory effects on reverse transcriptase activity and decrease fidelity <ce:cross-ref id="crf0475" refid="bib0055">[11]</ce:cross-ref>. However, oxidized mRNA can have a regulatory role in the cell <ce:cross-ref id="crf0480" refid="bib0060">[12]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0055" view="all">APE1 can cleave small interfering (si)RNA using its endonuclease activity, leading to RNA degradation <ce:cross-ref id="crf0485" refid="bib0065">[13]</ce:cross-ref>. Therefore, APE1 is a potential regulator of the mRNA pool, ensuring that lesioned RNA is not transcribed. APE1 binds to RNA with its 33-nucleotide N-terminal tail and acts upon RNA using its 3′-ribophosphate and 3′-exoribonuclease activity <ce:cross-ref id="crf0490" refid="bib0065">[13]</ce:cross-ref>. <ce:italic>In vitro</ce:italic>, APE1 can regulate cMyc mRNA levels via degradation <ce:cross-ref id="crf0495" refid="bib0065">[13]</ce:cross-ref>. Knockdown of APE1 results in an increased number of oxidized mRNAs, implying that APE1 is involved in mRNA cleansing <ce:cross-ref id="crf0500" refid="bib0065">[13]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0060" view="all">Relatedly, APE1 enhances post-translational maturation of miRNA-221/222, an RNA that promotes the Akt pathway and, therefore, cell survival and proliferation <ce:cross-ref id="crf0505" refid="bib0070">[14]</ce:cross-ref>. miR221/222 is oncogenic when upregulated, causing thyroid papillary carcinomas, glioblastomas, prostate cancer (PCa), and gastric carcinoma <ce:cross-ref id="crf0510" refid="bib0075">[15]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0030" view="all">
                     <ce:section-title id="sect0035">Role of APE1 in mitochondria and metabolism</ce:section-title>
                     <ce:para id="par0065" view="all">APE1 is necessary for mitochondrial BER <ce:cross-ref id="crf0515" refid="bib0080">[16]</ce:cross-ref>. The mitochondrial-targeting sequence at the C terminus of APE1 interacts with mitochondrial import and assembly protein Mia40, allowing APE1 to accumulate in the inner membrane space to further participate in mitochondrial BER and stabilize the mitochondrial genome <ce:cross-ref id="crf0520" refid="bib0085">[17]</ce:cross-ref>. Moreover, inhibition of the endonuclease function of APE1, but not its redox function or interaction with NPM1, results in increased expression of P53, decreased cellular metabolism, reduced mitochondrial function, and greater sensitivity to genotoxicity in colon cells <ce:cross-ref id="crf0525" refid="bib0090">[18]</ce:cross-ref>. Research has suggested that both the DNA repair and redox functions of APE1 are essential to maintain the integrity of mitochondria <ce:cross-ref id="crf0530" refid="bib0090">[18]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0035" view="all">
                     <ce:section-title id="sect0040">Nucleophosmin/nucleoplasmin and APE1 interaction</ce:section-title>
                     <ce:para id="par0070" view="all">Nucleophosmin/nucleoplasmin (NPM1) is a protein involved in histone chaperones, DNA repair, regulation of ARF-p53, apoptosis inhibition, ribosome formation, and transport of basic proteins to the nucleolus <ce:cross-refs id="crfs0065" refid="bib0095 bib0100">[19,20]</ce:cross-refs>. It is found primarily in the granular nucleolus, but is also shuttled to the nucleus and cytoplasm <ce:cross-refs id="crfs0070" refid="bib0095 bib0100">[19,20]</ce:cross-refs>. NPM1 binds preferentially to G-quadruplex-forming nucleotides and can bind both double and single-stranded DNA <ce:cross-refs id="crfs0075" refid="bib0095 bib0100">[19,20]</ce:cross-refs>.</ce:para>
                     <ce:para id="par0075" view="all">NPM1 controls the localization of BER proteins, including APE1 <ce:cross-ref id="crf0535" refid="bib0105">[21]</ce:cross-ref>. Binding of APE1 to NPM1 is necessary for APE1 to be translocated to the nucleolus <ce:cross-ref id="crf0540" refid="bib0105">[21]</ce:cross-ref>. A mutant of NMP1 (NPM1c+) causes acute myeloid leukemia, a disease in which NPM1 is translocated to the cytoplasm, bringing APE1 to the cytoplasm <ce:cross-refs id="crfs0080" refid="bib0110 bib0115 bib0120">[22–24]</ce:cross-refs>. The localization of APE1 to the cytoplasm reduces its ability to function in BER, as well as inhibiting NPM1 <ce:cross-refs id="crfs0085" refid="bib0110 bib0115 bib0120">[22–24]</ce:cross-refs>. In a study of triple-negative breast cancer (TNBC) cell lines, treatment with platinum-based compounds caused NMP1 and APE1 to be shuttled out of the nucleolus and into the nucleoplasm <ce:cross-ref id="crf0545" refid="bib0125">[25]</ce:cross-ref>. This change in localization sensitized the cells to other cytotoxicity agents <ce:cross-ref id="crf0550" refid="bib0125">[25]</ce:cross-ref>.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0040" view="all">
                  <ce:section-title id="sect0045">APE1 as a therapeutic opportunity for various cancers</ce:section-title>
                  <ce:para id="par0080" view="all">APE1 is one among many deregulated proteins involved in cancer survival signaling pathways <ce:cross-ref id="crf0555" refid="bib0130">[26]</ce:cross-ref>. Its multifunctional role in DNA repair, TF redox signaling, miRNA metabolism, and RNA quality control makes it a significant therapeutic target in cancers of pancreas, bladder, colon, rectum, blood, peripheral neurons, lung, breast, prostate, liver, ovary, bone, cervix, skin, glial cells, and head and neck <ce:cross-ref id="crf0560" refid="bib0005">[1]</ce:cross-ref>. Its aberrant expression levels in many of these cancers are associated with chemo and radioresistance. As evidenced by current studies, combinatorial synthetic lethal targeting of APE1 in conjunction with metabolic or hypoxic pathway regulators might be an effective strategy for improving the response rate to treatment. A brief discussion of APE1 in cancer is provided herein, with additional listings in <ce:cross-ref id="crf0565" refid="tbl0010">Table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl0010"/></ce:float-anchor>.</ce:para>
                  <ce:section id="sec0045" view="all">
                     <ce:section-title id="sect0050">Overexpression</ce:section-title>
                     <ce:para id="par0085" view="all">APE1 is overexpressed in nonsmall cell lung cancer (NSCLC) tumor tissues, with patients having lower APE1 levels showing significantly longer progression-free survival and longer overall survival <ce:cross-ref id="crf0570" refid="bib0135">[27]</ce:cross-ref>. In TNBC, APE1 overexpression correlated with malignant clinical manifestation (median survival: 82.0 months for low versus 66.9 months for high expression) <ce:cross-ref id="crf0575" refid="bib0140">[28]</ce:cross-ref>. High-grade PCa tissues and prostatic intraepithelial neoplasia (PIN) show elevated APE1 levels compared with benign hypertrophy (BPH) and normal prostate sections, which was strongly associated with tumor grade, tumor stage, and early recurrence <ce:cross-ref id="crf0580" refid="bib0145">[29]</ce:cross-ref>. Its interactions with STAT3 under oxidative stress appear to drive PCa progression <ce:cross-ref id="crf0585" refid="bib0150">[30]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0090" view="all">APE1 is also constitutively overexpressed in esophageal adenocarcinoma (EAC), in which its redox function via the epidermal growth factor receptor (EGFR)–STAT3 axis, Cyclooxygenase-2–vascular endothelial growth factor (COX2/VEGF) regulation, activation of NFκB–p65, as well as the repair function of APE1 are actively involved <ce:cross-ref id="crf0590" refid="bib0155">[31]</ce:cross-ref>. APE1 expression is high in human bladder cancer (BCa) tissue relative to benign urothelium. Fishel <ce:italic>et al</ce:italic>. demonstrated that <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> treatment with novel redox selective APE1 inhibitors effectively reduced BCa tumor proliferation and growth and, in combination with standard-of care chemotherapy cisplatin, could be more effective than cisplatin alone <ce:cross-ref id="crf0595" refid="bib0160">[32]</ce:cross-ref>. Studies also demonstrated that urinary APE1 levels could be a reliable diagnostic biomarker for BCa (area under the curve 0.83) because APE1 levels were associated with tumor grade stage, muscle invasion, and disease recurrence <ce:cross-refs id="crfs0090" refid="bib0165 bib0170 bib0175">[33–35]</ce:cross-refs>.</ce:para>
                     <ce:para id="par0095" view="all">The repair function of APE1 is associated with telomere maintenance. A deficiency of APE1 [APE1 short hairpin (sh)RNA] controls cellular fate in an hTERT-dependent manner. Li <ce:italic>et al</ce:italic>. <ce:cross-ref id="crf0600" refid="bib0180">[36]</ce:cross-ref> demonstrated that APE1 mediated senescence in hTERT-negative BJ cells while promoting apoptosis in hTERT-positive BJ cells. This effect could be the result of the dislocation of shelterin (telomere binding protein complex) proteins, such as TRF1, TRF2, and POT1, from telomeres <ce:cross-ref id="crf0605" refid="bib0185">[37]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0050" view="all">
                     <ce:section-title id="sect0055">Functional significance</ce:section-title>
                     <ce:para id="par0100" view="all">Reduction in APE1 levels increase breast cancer (BC) susceptibility to olaparib treatment. APE1 and its regulator NPM1 rescue TNBC cells from platinating compound cytotoxicity <ce:cross-ref id="crf0610" refid="bib0125">[25]</ce:cross-ref>. Xie <ce:italic>et al</ce:italic>. observed elevated levels of secreted APE1 within the serum of patients with oral squamous cell carcinoma (OSCC) and proposed that this might serve as a diagnostic biomarker for OSCC. Indeed, lower levels of APE1 were associated with longer disease-free survival after cisplatin therapy <ce:cross-ref id="crf0615" refid="bib0190">[38]</ce:cross-ref>. Redox inhibition of APE1 using APX3330 (E3330) in combination with 5-FU resulted in enhanced colorectal cancer (CRC) tumor regression. In contrast, inhibition of the endonuclease activity of APE1, but not the redox function or the interaction with NPM1, triggers p53-mediated effects on cell metabolism in colon cancer cell lines, sensitizing them to genotoxic treatment <ce:cross-ref id="crf0620" refid="bib0090">[18]</ce:cross-ref>. In hepatocellular carcinoma (HCC), upregulation of APE1 mRNA is linked with disease progression <ce:cross-ref id="crf0625" refid="bib0195">[39]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0105" view="all">Logsdon <ce:italic>et al</ce:italic>. demonstrated effective blockade of the APE1–HIF1–CA9 pathway, creating a ‘drug-synthetic lethality’, which further resulted in enhanced inhibition of 3D pancreatic ductal adenocarcinoma (PDAC) tumor growth <ce:cross-ref id="crf0630" refid="bib0130">[26]</ce:cross-ref>. Exploring a different synthetic lethality, Cardoso <ce:italic>et al.</ce:italic> demonstrated that the redox function of APE1 directly regulates STAT3 transcriptional activity and, hence, concurrent blockade of STAT3 and APE1 redox function synergistically can inhibit PDAC growth <ce:cross-ref id="crf0635" refid="bib0160">[32]</ce:cross-ref>. In myeloid leukemia cell lines, redox inhibition of APE1 using APX3330 synergized with retinoic acid (RA) mediated differentiation (shift of population to positive CD11b marker) <ce:cross-ref id="crf0640" refid="bib0160">[32]</ce:cross-ref> and triggered apoptosis of leukemia T cells [including drug-resistant, relapsed (T cell acute lymphoblastic leukemia (T-ALL) cells] by downregulating the transcription of the prosurvival genes <ce:italic>Bcl-xL</ce:italic> and <ce:italic>Survivin</ce:italic> 
                        <ce:cross-ref id="crf0645" refid="bib0200">[40]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0110" view="all">In patients with glioblastoma (GBM), oxidative stress elevated APE1 levels, thus increasing the repair of abasic sites resulting in enhanced drug resistance. The redox as well as repair function of APE1 also contribute to temozolomide (TMZ) resistance <ce:cross-ref id="crf0650" refid="bib0205">[41]</ce:cross-ref>. Malignant peripheral nerve sheath tumor (MPNST), a soft-tissue sarcoma arising from peripheral nerve sheath, which is common among patients with neurofibromatosis I, has considerably limited treatment options <ce:cross-ref id="crf0655" refid="bib0210">[42]</ce:cross-ref>. The STAT3–HIF1α–VEGF-A signaling axis drives MPNST progression and suggests targeting of APE1 as a viable treatment strategy <ce:cross-ref id="crf0660" refid="bib0215">[43]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0055" view="all">
                     <ce:section-title id="sect0060">Polymorphisms</ce:section-title>
                     <ce:para id="par0115" view="all">Emerging evidence suggests that certain APE1 polymorphisms are clinically relevant and contribute to cancer pathology <ce:cross-ref id="crf0665" refid="bib0220">[44]</ce:cross-ref>. L104R, R237C, D148E, and D283G are the most common substitution mutations among many found in APE1 <ce:cross-ref id="crf0670" refid="bib0225">[45]</ce:cross-ref>. They are linked with acute adverse effects to radiotherapy and chemoresistance in BC and CRC <ce:cross-refs id="crfs0095" refid="bib0230 bib0235 bib0240 bib0245 bib0250">[46–50]</ce:cross-refs>. Most reported of the polymorphisms is Asp148Glu, the presence of which reduces the ability of APE1 to communicate with its BER partners <ce:cross-refs id="crfs0100" refid="bib0255 bib0260">[51,52]</ce:cross-refs>. In bladder cancer, APE1 is reported to be present as four variants: one with a single substitution (D148E) and three with double substitution mutations (I64V/D148E, W67R/D148E, and E86G/D148E). APE1 with D148E or I64V/D148E or E86G/D148E substitutions show expression levels and nuclear localization similar to WT APE1. However, APE1 with the W67R/D148E double substitution mutation was expressed in lower amounts and localized to the nucleolus. Also, increased secretion of APE1 D148E might result from the increased sensitivity of intracellular acetylation, as demonstrated using Trichostatin A (TSA, an HDAC inhibitor) <ce:cross-ref id="crf0675" refid="bib0170">[34]</ce:cross-ref>. These single nucleotide polymorphism (SNP) variants increase the risk of developing cancers of the lung (Ile64Val and Asp141Glu) <ce:cross-refs id="crfs0105" refid="bib0265 bib0270">[53,54]</ce:cross-refs> and prostate [in combination with other gene variants, such as XRCC1 Arg399Gln (a key protein in DNA repair)] <ce:cross-refs id="crfs0110" refid="bib0275 bib0280">[55,56]</ce:cross-refs>. Thus, it is important to further understand all functional variants of APE1 to define a link between its genetic variation, repair and/or redox function, and disease susceptibility.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0060" view="all">
                  <ce:section-title id="sect0065">The contribution of APE1 also extends to other disease pathologies</ce:section-title>
                  <ce:para id="par0120" view="all">APE1 has emerged as a therapeutic target for treating neovascular AMD and other neovascular diseases. The redox function of APE1 is required for normal retinal angiogenesis. APX3330 inhibited the proliferation, migration, and tube formation of mouse retinal vascular endothelial cells (RVECs) <ce:cross-ref id="crf0680" refid="bib0285">[57]</ce:cross-ref>. It also regulated the response of retinal pigment epithelium (RPEs) cells to oxidative stress by reducing NFκB and HIF1α activity <ce:cross-refs id="crfs0115" refid="bib0290 bib0295">[58,59]</ce:cross-refs>. APX2009 and APX2014, which are second-generation APX3330 analogs, further blocked endothelial cell proliferation, tube formation, migration, and NFκB activity under <ce:italic>in vitro</ce:italic> conditions and blocked angiogenesis <ce:italic>ex vivo</ce:italic> 
                     <ce:cross-ref id="crf0685" refid="bib0300">[60]</ce:cross-ref>. A Phase II trial using APX3330 to treat DR and DME is planned to start in early 2021.</ce:para>
                  <ce:para id="par0125" view="all">IBD is characterized by the loss of redox homeostasis resulting in enteric nervous system (ENS) damage and gastrointestinal (GI) dysfunction. IBD has no cure, defies early detection, and lacks reliable biomarkers, thereby increases the risk of colon cancer. Crohn’s disease and ulcerative colitis (UC) are its principal forms <ce:cross-ref id="crf0690" refid="bib0305">[61]</ce:cross-ref>. Responsible factors include NFκB, AP-1, HIF, and STAT3, TFs that are regulated by APE1. In a recently published study, inhibition of APE1 redox function by APX3330 reduced enteric neuropathy and intestinal dysfunction <ce:cross-ref id="crf0695" refid="bib0310">[62]</ce:cross-ref>. Additionally, polymorphisms of APE1 (Asp148Glu) and XRCC-1 (Arg399Gln) have also been found to be associated with UC <ce:cross-ref id="crf0700" refid="bib0315">[63]</ce:cross-ref>. Given these results, targeting APE1 redox signaling appears to be an attractive avenue of translational research in this area.</ce:para>
               </ce:section>
               <ce:section id="sec0065" view="all">
                  <ce:section-title id="sect0070">Inhibitors of APE1 DNA repair or redox signaling</ce:section-title>
                  <ce:para id="par0130" view="all">APE1 has been implicated in resistance to DNA interactive drugs and cancer pathogenesis. Therefore, APE1 is a crucial node to target for cancer therapeutics. For example, inhibition of the DNA repair function of APE1 sensitized resistant tumors to DNA interactive drugs (bleomycin, carmustine, TMZ, and gemcitabine) and increased levels of apoptosis <ce:cross-ref id="crf0705" refid="bib0005">[1]</ce:cross-ref>. Inhibition of the redox function of APE1 prevented DNA binding of cancer-associated TFs and subsequently their effects on the transcriptome <ce:cross-ref id="crf0710" refid="bib0005">[1]</ce:cross-ref>. Thus, there is a vital need to identify effective inhibitors for both the repair and redox functions of APE1. Several studies have investigated both DNA repair and redox inhibition through various screening paradigms. A list of APE1 inhibitors at all stages of study are listed in <ce:cross-ref id="crf0715" refid="tbl0015">Table 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl0015"/></ce:float-anchor>.</ce:para>
               </ce:section>
               <ce:section id="sec0070" view="all">
                  <ce:section-title id="sect0075">APE1 DNA repair function inhibitors</ce:section-title>
                  <ce:para id="par0135" view="all">Methoxyamine (MX), one of the first studied molecules affecting APE1 repair activities, is an alkoxyamine derivative that acts as an indirect inhibitor of the repair function of APE1 <ce:cross-ref id="crf0720" refid="bib0320">[64]</ce:cross-ref>. MX reacts with the open-ring sugar in the DNA after a damaged nucleotide has been removed via glycosylase, thereby blocking APE1 endonuclease activity. In xenograft models of colon cancer, the addition of MX increased the cytotoxicity of TMZ, a DNA interactive drug <ce:cross-ref id="crf0725" refid="bib0320">[64]</ce:cross-ref>. However, MX is not a direct inhibitor of the DNA repair activity of APE1, binding to AP sites and preventing APE1 cleavage. MX advanced to clinical trials, with eight trials attempted. In a Phase II trial completed in 2019 the response criteria was not met (NCT02395692). A current Phase I/II trial initiated in 2013 for relapsed solid tumors and lymphoma is estimated to complete in 2021 with 140 patients (NCT01851369). To date, clinical studies have not shown success with MX.</ce:para>
                  <ce:para id="par0140" view="all">A 5-point pharmacophore model for APE1 small-molecule inhibitors was used to identify new compounds <ce:cross-ref id="crf0730" refid="bib0325">[65]</ce:cross-ref>. The authors conducted an <ce:italic>in silico</ce:italic> screen of 10,159 compounds and ten were identified as potential APE1 endonuclease inhibitors based on the quality of their virtual docking. Further analysis was performed on four compounds with a 2-methyl-4-amino-6,7-dioxoloquinoline core (AJAY 1–4). AJAY-4 exhibited the lowest overall median growth inhibition concentration (∼4<ce:hsp sp="0.25"/></ce:hsp>μM) in an NCI-60 cell line panel. The mechanism of action is suggested to be the build-up of AP sites, which activates PARP and PARP cleavage, subsequently triggering caspase-3 and caspase-7-associated apoptosis. However, none of these compounds have advanced to significant <ce:italic>in vivo</ce:italic> studies or clinical trials.</ce:para>
                  <ce:para id="par0145" view="all">A fluorescence-based quantitative high-throughput screen (HTS) of 352 489 small molecules from the NIH Molecular Libraries Small Molecule Repository was performed <ce:cross-ref id="crf0735" refid="bib0330">[66]</ce:cross-ref>. Compound 3, with a chemical structure of <ce:italic>N</ce:italic>-(3-(benzo[<ce:italic>d</ce:italic>]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno [2,3-<ce:italic>c</ce:italic>]pyridin-2-yl)acetamide, was identified to inhibit APE1 endonuclease activity at low micromolar concentrations in HeLa cells. From whole-cell extract assays, compound 3 potentiated cytotoxicity of methyl methanesulfonate (MMS) and TMZ and caused hyperaccumulation of AP sites in HeLa cells when combined with MMS <ce:cross-ref id="crf0740" refid="bib0330">[66]</ce:cross-ref>. Nevertheless, this compound has not significantly advanced beyond <ce:italic>in vitro</ce:italic> studies.</ce:para>
                  <ce:para id="par0150" view="all">
                     <ce:italic>In silico</ce:italic> analysis of a library of 15- to 16-membered macrocycles from the Boston University Center for Molecular Diversity (BU-CMD) screening collection, led to selection of 66 potential inhibitors of APE1 with favorable preliminary docking results <ce:cross-ref id="crf0745" refid="bib0335">[67]</ce:cross-ref>. From the 66 compounds assayed, four exhibited concentration-dependent inhibition of APE1 endonuclease activity (MC043, MC047, MC042, and MC018). The chemotype was further explored; three second-generation macrocyclic lactams 13, 21, 24 assessed by comet analysis following treatment with MMS exhibited potent inhibition of APE1 endonuclease activity. These results suggest further development of these chemotypes as APE1 repair inhibitors.</ce:para>
                  <ce:para id="par0155" view="all">There are numerous other one-off studies of reported APE1 repair inhibitors, such as 7-nitroindole-2-carboxylic acid (NCA) and CRT0044876. However, for multiple reasons, including lack of favorable drug-like properties or of <ce:italic>in vivo</ce:italic> success, these compounds did not progress to lead optimization <ce:cross-refs id="crfs0120" refid="bib0005 bib0340 bib0345">[1,68,69]</ce:cross-refs>. Additional repair inhibitors are listed in <ce:cross-ref id="crf0750" refid="tbl0015">Table 3</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0075" view="all">
                  <ce:section-title id="sect0080">APE1 redox inhibitors</ce:section-title>
                  <ce:para id="par0160" view="all">Although there have been several studies looking at APE1 redox inhibition, including several compounds from natural sources, none of these natural products have demonstrated specific or direct inhibition of redox signaling associated with APE1 <ce:cross-ref id="crf0755" refid="bib0005">[1]</ce:cross-ref>. An example of these include resveratrol, which has varied bioavailability, sporadic <ce:italic>in vivo</ce:italic> efficacy and low molecular specificity <ce:cross-ref id="crf0760" refid="bib0340">[68]</ce:cross-ref>. Soy isoflavones, such as genistein and daidzein, have been suggested to be inhibitors of APE1 redox function; however, they do not directly inhibit the redox function of APE1, have significant off target effects, and have not proved valid as APE1 redox inhibitors <ce:cross-ref id="crf0765" refid="bib0005">[1]</ce:cross-ref>. Another low-specificity natural product, curcumin, has significant off target effects <ce:cross-ref id="crf0770" refid="bib0005">[1]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0165" view="all">By contrast, a series of compounds have been developed that are specifically targeted to APE1 redox signaling inhibition and blocking activation of downstream TFs, such as HIF-1α, NFκB, STAT3 and others <ce:cross-ref id="crf0775" refid="bib0005">[1]</ce:cross-ref>. APX3330 is the only APE1 redox inhibitor, or any APE1 inhibitor, to enter and complete Phase I clinical trials (NCT03375086). It is a dimethoxy benzoquinone specific for the redox signaling function of APE1 without negatively altering the DNA repair function of APE1 <ce:cross-ref id="crf0780" refid="bib0005">[1]</ce:cross-ref>. The nucleophilic Cys65 residue responsible for redox signaling in APE1 is blocked by APX3330 and prevents the ability of APE1 to act as a reducing agent on the downstream TFs. Numerous studies have demonstrated the specific inhibition of APE1 redox signaling function by APX3330 in numerous models both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>, including pancreatic cancer, BCa, PCa, leukemia <ce:cross-ref id="crf0785" refid="bib0005">[1]</ce:cross-ref> and MPNSTs <ce:cross-ref id="crf0790" refid="bib0350">[70]</ce:cross-ref>. Furthermore, second-generation APX compounds, such as APX2007, APX2009, APX2014, and APX2032, are naphthoquinones, in which adjacent dimethoxy moieties in APX3330 are replaced by a second aromatic ring. The lipophilic side chain is shorter and carboxamide is added to replace carboxylic acid, which removes the negative charge present in APX3330. These alterations demonstrated increased efficacy in tumor studies as well as in other disease models reliant on NFκB, HIF-1α, or STAT3, such as inflammation and angiogenesis-driven retinal diseases and IBD <ce:cross-refs id="crfs0125" refid="bib0005 bib0310">[1,62]</ce:cross-refs>. Protective effects on dorsal root ganglion and enteric neurons for chemotherapy-induced peripheral neuropathy (CIPN) and IBD have also been observed with APX compounds <ce:cross-ref id="crf0795" refid="bib0005">[1]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0080" view="all">
                  <ce:section-title id="sect0085">Clinical trials</ce:section-title>
                  <ce:para id="par0170" view="all">A Phase I clinical trial (NCT03375086) of APX3330 in patients with recently progressive advanced solid tumors was initiated in early 2018. Patients received oral doses of APX3330 on a twice-daily (b.i.d.) schedule during continuous 21-day (d) cycles until disease progression or drug intolerance. The study was initiated using single-patient cohorts until the occurrence of ≥G2 (grade 2) toxicity, at which time accrual proceeded using a standard 3<ce:hsp sp="0.25"/></ce:hsp>+<ce:hsp sp="0.25"/></ce:hsp>3 design. Additional patients per cohort were enrolled to obtain blood, circulating tumor cell (CTC), and biopsy samples as needed and to define the recommended Phase II study dose (RP2D). The study accrued 19 patients (13 males and 6 females; median age of 69 years). APX3330 was administered in escalating dose cohorts from 240<ce:hsp sp="0.25"/></ce:hsp>mg/d to 720<ce:hsp sp="0.25"/></ce:hsp>mg/d and was well tolerated through 600<ce:hsp sp="0.25"/></ce:hsp>mg/d, now defined as the RP2D <ce:cross-refs id="crfs0130" refid="bib0355 bib0360">[71,72]</ce:cross-refs>. The dose-limiting toxicity (at 720<ce:hsp sp="0.25"/></ce:hsp>mg/d) was a pruritic, diffuse macular rash that was spontaneously reversible.</ce:para>
                  <ce:para id="par0175" view="all">Six of 19 patients had disease stabilization for ≥12 weeks; and 4 of 19 for ≥36 weeks, including 252 d (PCa), 337 d (melanoma), and 421 d (endometrial cancer). One partial response was noted in a patient with CRC on study for 357 d. Serum levels of APE1 decreased after administration of APX3330, as did CTCs in seven out of 16 patients evaluated. Tissue biopsy evaluations indicated reduced levels of transcription activity for regulators of cancer survival pathways (e.g., NFκB, HIF1, and STAT3), indicating that APX3330 mediates the redox activity of the APE1 protein target as expected <ce:cross-refs id="crfs0135" refid="bib0355 bib0360">[71,72]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0180" view="all">Based upon these promising results, Apexian Pharmaceuticals (Indianapolis, IN, USA) is planning additional clinical trials in indications where APE1 functions to control the activity of NFκB, HIF, and STAT3, including a Phase II trial for patients with DME and DR as part of a licensing agreement with Ocuphire Pharma (Farmington Hill, MI). Additional indications are undergoing evaluation.</ce:para>
               </ce:section>
               <ce:section id="sec0085" view="all">
                  <ce:section-title id="sect0090">Future directions</ce:section-title>
                  <ce:para id="par0185" view="all">With the surge in sequencing and big data platforms, several studies confirmed the known roles of APE1 in both tumor and normal cells as well as illuminating new pathways and interactions of APE1. The validation of these findings through drug screening and molecular studies will impact the way we understand the functions of APE1 within living cells and how we understand it as a target in cancer therapy. Here, we highlight recent relevant findings in which multi-omic approaches were used to better understand APE1 as a cancer target as well as pointing toward new clinical applications.</ce:para>
                  <ce:para id="par0190" view="all">To study the effects of this important protein, APE1 overexpression and knockdown approaches were used in a variety of cell types with various global gene or protein expression analyses. The compilation of these studies clearly demonstrate that certain pathways repeatedly are affected. These include mitochondria-related processes, including oxidative phosphorylation and metabolism, transcriptional regulation, RNA metabolism, cell cycle, DNA repair, and stress responses, including oxidative stress signaling <ce:cross-refs id="crfs0140" refid="bib0060 bib0365 bib0370 bib0375 bib0380">[12,73–76]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0195" view="all">Previous preclinical and clinical studies suggest that there will not be one ‘magic bullet’ or singular target in hard-to-treat solid tumors and that multitargeted combination treatments that synergize will be more efficacious. Recent efforts have included trying to combine ‘omics data with other publicly available databases, such as Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), and Cancer Therapeutics Response Portal (CTRP), to determine which clinical agents will combine with APE1 inhibitors to create a drug-induced synthetic lethal event <ce:cross-refs id="crfs0145" refid="bib0385 bib0390">[77,78]</ce:cross-refs>. Using these tools to incorporate transcriptomic and drug sensitivity data of cancer cell lines from the public domain, predictions of which US Food and Drug Administration (FDA)-approved agents are likely to synergize with APX3330 are generated. Some classes of drug that are predicted to synergize with APE1 inhibition are receptor tyrosine kinases (RTKs), DNA-damaging agents and nucleoside analogs, and HDAC inhibitors. Combination drug screening is underway currently and the goal is to generate novel multitargeted drug combinations involving APE1 inhibition and improved response in <ce:italic>in vivo</ce:italic> and <ce:italic>in vitr</ce:italic>o systems.</ce:para>
                  <ce:para id="par0200" view="all">Pancreatic cancer studies combining APE1 silencing with single-cell RNA-sequencing led to elucidation of pathways including EIF2, mTOR, and protein kinase A (PKA). These pathways were significantly affected by APE1 signaling, had not previously been reported, and are related to translation as well as PKA, which might be contribute to drug resistance and/or the energy-sensing capabilities of the cell <ce:cross-ref id="crf0800" refid="bib0370">[74]</ce:cross-ref>. These pathway perturbations might be the result of the blockade of HIF1α signaling because APE1 regulates its DNA binding, and it is well known that these pathways can directly or indirectly influence HIF1α activity. There were also pathways in common with other previously published studies, including DNA repair, DNA damage, and apoptosis pathway perturbation. Within these low-passage patient-derived cells, 15% (3/20) of the significantly changed pathways were mitochondria-related processes.</ce:para>
                  <ce:para id="par0205" view="all">Based on a clear demonstration that APE1 signaling affects mitochondria, the combination of metabolic inhibitors with APE1 inhibition has the potential to be therapeutically detrimental to cancer cells. There are many drugs that are in use in the clinic that target metabolism and could be repurposed or tested in combination with APE1 inhibitors <ce:cross-ref id="crf0805" refid="bib0395">[79]</ce:cross-ref>. Currently, it is not clear whether the redox activity or the DNA repair activity or both exert these effects on mitochondrial function. Data suggest that a large component of the effect on the TCA cycle results from the redox signaling activity of APE1. The effects of APE1 siRNA on the TCA cycle are similar to the reduction in function seen with APE1 redox inhibitor, APX2009 as assayed by gene expression as well as a mitochondria functional assay (Caston <ce:italic>et al</ce:italic>., unpublished data, 2020).</ce:para>
               </ce:section>
               <ce:section id="sec0090" view="all">
                  <ce:section-title id="sect0095">Concluding remarks</ce:section-title>
                  <ce:para id="par0210" view="all">In summary, as our understanding of the pathways in cancer and other diseases that intersect and depend upon APE1 signaling deepen, we will be able to design single-agent and combination therapies for patients. Although a significant amount of focus has been on the role of APE1 in cancer, recent findings support APE1 as a target in other indications, including ocular diseases (DME, DR, and AMD), IBD and other indications where APE1 regulation of TFs impacts important pathways in these diseases.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0100">Acknowledgments</ce:section-title>
               <ce:para id="par0215" view="all">M.R.K. and M.L.F. were supported by grants from the <ce:grant-sponsor id="gs0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Institute of Health and National Cancer Institute</ce:grant-sponsor>
                  <ce:grant-number refid="gs0005">R01CA167291</ce:grant-number>, <ce:grant-number refid="gs0005">R01CA167291-S1</ce:grant-number> and DOD grant <ce:grant-number refid="gs0005">W81XWH1910217</ce:grant-number>. M.R.K. was also supported by NIH/NCI grants <ce:grant-number refid="gs0005">R01CA205166</ce:grant-number>, <ce:grant-number refid="gs0005">R01CA231267</ce:grant-number>, <ce:grant-number refid="gs0005">R01EY031939</ce:grant-number> and <ce:grant-number refid="gs0005">R01HL140961</ce:grant-number> and M.L.F. was supported by NIH/NCI grants <ce:grant-number refid="gs0005">U01HL143403</ce:grant-number>, <ce:grant-number refid="gs0005">R01CA211098</ce:grant-number> and <ce:grant-number refid="gs0005">R01NF180045</ce:grant-number>. M.R.K. and M.L.F. were additionally supported by the <ce:grant-sponsor id="gs0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Riley Children’s Foundation</ce:grant-sponsor> and the <ce:grant-sponsor id="gs0015" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Tom Wood Lexus Foundation</ce:grant-sponsor>.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0105">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting the Ref-1–APE1 node in cancer signaling and other diseases: from bench to clinic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>NPJ: Precis. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Wallace</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Base excision repair: a critical player in many games</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>DNA Repair (Amst)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Ishchenko</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Uncoupling of the base excision and nucleotide incision repair pathways reveals their respective biological roles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2564</sb:first-page>
                              <sb:last-page>2569</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Whitaker</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular snapshots of APE1 proofreading mismatches and removing DNA damage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>399</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gros</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The major human AP endonuclease (Ape1) is involved in the nucleotide incision repair pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic. Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>73</sb:first-page>
                              <sb:last-page>81</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of the redox activity and disulfide bond formation in apurinic/apyrimidinic endonuclease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>695</sb:first-page>
                              <sb:last-page>705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Logsdon</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of HIF1a under hypoxia by APE1/Ref-1 impacts CA9 expression: dual-targeting in patient-derived 3D pancreatic cancer models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2722</sb:first-page>
                              <sb:last-page>2732</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fishel</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1698</sb:first-page>
                              <sb:last-page>1708</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Zaher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How do cells cope with RNA damage and its consequences?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>294</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>41</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15158</sb:first-page>
                              <sb:last-page>15171</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RNA damage and surveillance under oxidative stress</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>IUBMB Life</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>581</sb:first-page>
                              <sb:last-page>588</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Wurtmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Wolin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RNA under attack: cellular handling of RNA damage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Biochem. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34</sb:first-page>
                              <sb:last-page>49</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Antoniali</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>797</sb:first-page>
                              <sb:last-page>815</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RNA-cleaving properties of human apurinic/apyrimidinic endonuclease 1 (APE1)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12</sb:first-page>
                              <sb:last-page>25</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Tell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intrusion of a DNA repair protein in the RNome world: is this the beginning of a new era?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>366</sb:first-page>
                              <sb:last-page>371</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Garofalo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>miR221/222 in cancer: their role in tumor progression and response to therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27</sb:first-page>
                              <sb:last-page>33</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Chattopadhyay</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2067</sb:first-page>
                              <sb:last-page>2076</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barchiesi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitochondrial translocation of APE1 relies on the MIA pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5451</sb:first-page>
                              <sb:last-page>5464</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Codrich</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>DNA Repair</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>102675</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Heath</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological and clinical consequences of NPM1 mutations in AML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>807</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Box</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nucleophosmin: from structure and function to disease development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Poletto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Biol. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1641</sb:first-page>
                              <sb:last-page>1652</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Colombo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>23</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2595</sb:first-page>
                              <sb:last-page>2609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Banuelos</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recognition of intermolecular G-quadruplexes by full length nucleophosmin. Effect of a leukaemia-associated mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>587</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>14</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2254</sb:first-page>
                              <sb:last-page>2259</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chiarella</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3228</sb:first-page>
                              <sb:last-page>3239</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Malfatti</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Logsdon</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13759</sb:first-page>
                              <sb:last-page>13773</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4406</sb:first-page>
                              <sb:last-page>4419</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumour Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>9</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>McIlwain</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10962</sb:first-page>
                              <sb:last-page>10977</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cocchiola</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1815</sb:first-page>
                              <sb:last-page>1832</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1 upregulates MMP-14 via redox-sensitive ARF6-mediated recycling to promote cell invasion of esophageal adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4426</sb:first-page>
                              <sb:last-page>4438</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Fishel</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-tumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1947</sb:first-page>
                              <sb:last-page>1960</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Urinary APE1/Ref-1: a potential bladder cancer biomarker</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis. Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2016</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7276502</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Altered secretory activity of APE1/Ref-1 D148E variants identified in human patients with bladder cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. Neurourol. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl. 1</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S30</sb:first-page>
                              <sb:last-page>S37</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1/Ref-1 as a serological biomarker for the detection of bladder cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>823</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1 deficiency promotes cellular senescence and premature aging features</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5664</sb:first-page>
                              <sb:last-page>5677</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Madlener</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Essential role for mammalian apurinic/apyrimidinic (AP) endonuclease Ape1/Ref-1 in telomere maintenance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>44</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17844</sb:first-page>
                              <sb:last-page>17849</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apurinic/apyrimidinic endonuclease 1/redox factor-1 could serve as a potential serological biomarker for the diagnosis and prognosis of oral squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Oral Maxillofac. Surg.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>859</sb:first-page>
                              <sb:last-page>866</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pascut</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>394</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ref-1/APE1 as a transcriptional regulator and novel therapeutic target in pediatric T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1401</sb:first-page>
                              <sb:last-page>1411</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Cholia</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Metab. Brain Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1307</sb:first-page>
                              <sb:last-page>1326</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Bin Samsuddin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Bin Omar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Malignant peripheral nerve sheath tumor: treat or not treat?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Asian J. Neurosurg.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>283</sb:first-page>
                              <sb:last-page>285</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Rad</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 and HIF1α signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1149</sb:first-page>
                              <sb:last-page>1160</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lirussi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1 polymorphic variants cause persistent genomic stress and affect cancer cell proliferation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Oncotar.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>26293</sb:first-page>
                              <sb:last-page>26306</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.Z.</ce:given-name>
                                 <ce:surname>Hadi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functional characterization of Ape1 variants identified in the human population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3871</sb:first-page>
                              <sb:last-page>3879</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chang-Claude</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4802</sb:first-page>
                              <sb:last-page>4809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Canbay</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Res. Opin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1295</sb:first-page>
                              <sb:last-page>1302</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a northeast Chinese population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>505</sb:first-page>
                              <sb:last-page>513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1 polymorphisms are associated with colorectal cancer susceptibility in Chinese Hans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>World J. Gastroenterol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>26</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8700</sb:first-page>
                              <sb:last-page>8708</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The APE1 Asp148Glu polymorphism and colorectal cancer susceptibility: a meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumour Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2529</sb:first-page>
                              <sb:last-page>2535</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17333</sb:first-page>
                              <sb:last-page>17343</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>AlMutairi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association of DNA repair gene APE1 Asp148Glu polymorphism with breast cancer risk</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dis. Markers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2015</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genetic polymorphism of DNA base-excision repair genes (APE1, OGG1 and XRCC1) and their correlation with risk of lung cancer in a Chinese population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Med. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>226</sb:first-page>
                              <sb:last-page>234</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FASEB J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3459</sb:first-page>
                              <sb:last-page>3469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Urol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>175</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>discussion 112</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Genet. Genomics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>281</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Antioxid. Redox. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1853</sb:first-page>
                              <sb:last-page>1867</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Redox. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>485</sb:first-page>
                              <sb:last-page>494</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of choroidal neovascularization through inhibition of APE1/Ref-1 redox activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. Ophthalmol. Vis. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4461</sb:first-page>
                              <sb:last-page>4469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.P.B.</ce:given-name>
                                 <ce:surname>Sardar Pasha</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>367</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Serum metabolomics identifies altered bioenergetics, signaling cascades in parallel with exposome markers in Crohn’s disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>449</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sahakian</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of AP/Ref -1 redox signalling alleviates intestinal dysfunction and damage to myenteric neurons in a mouse model of spontaneous chronic colitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inflamm. Bowel Dis.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1093/ibd/izaa161</ce:doi>
                        </sb:host>
                        <sb:comment>Online ahead of print; PMID: 32618996</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bardia</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functional polymorphisms in XRCC-1 and APE-1 contribute to increased apoptosis and risk of ulcerative colitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Inflammation Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>359</sb:first-page>
                              <sb:last-page>365</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liuzzi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition by methoxyamine of the apurinic/apyrimidinic endonuclease activity associated with pyrimidine dimer-DNA glycosylases from <ce:italic>Micrococcus luteus</ce:italic> and bacteriophage T4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>1987</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3315</sb:first-page>
                              <sb:last-page>3321</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and activity of AP endonuclease-1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>79</sb:first-page>
                              <sb:last-page>93</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, biological evaluation, and structure–activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3101</sb:first-page>
                              <sb:last-page>3112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Trilles</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of macrocyclic inhibitors of apurinic/apyrimidinic endonuclease 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1988</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Fishel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Kelley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Aspects Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3-4</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>375</sb:first-page>
                              <sb:last-page>395</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Laev</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2531</sb:first-page>
                              <sb:last-page>2544</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signaling through Ref-1 and STAT3 in soft tissue sarcoma (MPNST) and the effects of perturbing this pathway on tumor cell survival and gene expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Supplement, pp. C017</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0355">
                     <ce:label>71</ce:label>
                     <sb:reference id="sbref0355">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shahda</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15_suppl</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>3097–3097</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0360">
                     <ce:label>72</ce:label>
                     <sb:reference id="sbref0360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15_suppl</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e14531–e14531</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0365">
                     <ce:label>73</ce:label>
                     <sb:reference id="sbref0365">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nassour</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29389</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0370">
                     <ce:label>74</ce:label>
                     <sb:reference id="sbref0370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1711</sb:first-page>
                              <sb:last-page>1732</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0375">
                     <ce:label>75</ce:label>
                     <sb:reference id="sbref0375">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>LTMG: a novel statistical modeling of transcriptional expression states in single-cell RNA-Seq data</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e111</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0380">
                     <ce:label>76</ce:label>
                     <sb:reference id="sbref0380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Illuzzi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tumor-associated APE1 variant exhibits reduced complementation efficiency but does not promote cancer cell phenotypes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Environ. Mol. Mutagen.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>84</sb:first-page>
                              <sb:last-page>98</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0385">
                     <ce:label>77</ce:label>
                     <sb:reference id="sbref0385">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Barretina</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>483</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7391</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>603</sb:first-page>
                              <sb:last-page>607</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0390">
                     <ce:label>78</ce:label>
                     <sb:reference id="sbref0390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Rees</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>109</sb:first-page>
                              <sb:last-page>116</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0395">
                     <ce:label>79</ce:label>
                     <sb:reference id="sbref0395">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Chandel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting mitochondria metabolism for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9</sb:first-page>
                              <sb:last-page>15</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0400">
                     <ce:label>80</ce:label>
                     <sb:reference id="sbref0400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cesaratto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1099</sb:first-page>
                              <sb:last-page>1112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0405">
                     <ce:label>81</ce:label>
                     <sb:reference id="sbref0405">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Going APE over Ref-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mutat. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>461</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>108</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0410">
                     <ce:label>82</ce:label>
                     <sb:reference id="sbref0410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Tell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Redox effector factor-1 regulates the activity of thyroid transcription factor 1 by controlling the redox state of the N transcriptional activation domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>17</sb:issue-nr>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14564</sb:first-page>
                              <sb:last-page>14574</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0415">
                     <ce:label>83</ce:label>
                     <sb:reference id="sbref0415">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.I.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of APE1 Asp148Glu polymorphisms on OPMD malignant transformation, and on susceptibility to and overall survival of oral cancer in Taiwan</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Head Neck</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1557</sb:first-page>
                              <sb:last-page>1564</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0420">
                     <ce:label>84</ce:label>
                     <sb:reference id="sbref0420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Breast Cancer Res. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>176</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>109</sb:first-page>
                              <sb:last-page>117</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0425">
                     <ce:label>85</ce:label>
                     <sb:reference id="sbref0425">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Poletto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophy. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>424</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34</sb:first-page>
                              <sb:last-page>39</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0430">
                     <ce:label>86</ce:label>
                     <sb:reference id="sbref0430">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>917</sb:first-page>
                              <sb:last-page>922</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0435">
                     <ce:label>87</ce:label>
                     <sb:reference id="sbref0435">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>27</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23383</sb:first-page>
                              <sb:last-page>23398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0440">
                     <ce:label>88</ce:label>
                     <sb:reference id="sbref0440">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Abdel-Fatah</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Breast Cancer Res. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>143</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>411</sb:first-page>
                              <sb:last-page>421</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0445">
                     <ce:label>89</ce:label>
                     <sb:reference id="sbref0445">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Woo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prognostic value of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e99528</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0450">
                     <ce:label>90</ce:label>
                     <sb:reference id="sbref0450">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>GADD45alpha sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>524</sb:first-page>
                              <sb:last-page>535</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0455">
                     <ce:label>92</ce:label>
                     <sb:reference id="sbref0455">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cytoplasmic APE1 promotes resistance response in osteosarcoma patients with cisplatin treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Biochem. Funct.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0460">
                     <ce:label>93</ce:label>
                     <sb:reference id="sbref0460">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>532</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7598</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>250</sb:first-page>
                              <sb:last-page>254</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0465">
                     <ce:label>94</ce:label>
                     <sb:reference id="sbref0465">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Kelley</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification and characterization of new chemical entities targeting Apurinic/Apyrimidinic Endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>359</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>300</sb:first-page>
                              <sb:last-page>309</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0470">
                     <ce:label>95</ce:label>
                     <sb:reference id="sbref0470">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Vision Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>93</sb:first-page>
                              <sb:last-page>100</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0475">
                     <ce:label>96</ce:label>
                     <sb:reference id="sbref0475">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bapat</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>334</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>988</sb:first-page>
                              <sb:last-page>998</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0480">
                     <ce:label>97</ce:label>
                     <sb:reference id="sbref0480">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Poletto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin (NPM1) interaction that display anti-tumor properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Carcinog.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>688</sb:first-page>
                              <sb:last-page>704</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0485">
                     <ce:label>98</ce:label>
                     <sb:reference id="sbref0485">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Madala</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based drug design to overcome temozolomide resistance in glioblastoma (GBM) through a dual inhibition of MGMT and base excision repair</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>AACR</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0490">
                     <ce:label>99</ce:label>
                     <sb:reference id="sbref0490">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Seiple</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>669</sb:first-page>
                              <sb:last-page>677</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0495">
                     <ce:label>100</ce:label>
                     <sb:reference id="sbref0495">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zawahir</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20</sb:first-page>
                              <sb:last-page>32</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0500">
                     <ce:label>101</ce:label>
                     <sb:reference id="sbref0500">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of new potential APE1 inhibitors by pharmacophore modeling and molecular docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genomics Inf.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>147</sb:first-page>
                              <sb:last-page>155</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0505">
                     <ce:label>102</ce:label>
                     <sb:reference id="sbref0505">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>McNeill</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functions of the major abasic endonuclease (APE1) in cell viability and genotoxin resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mutagenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27</sb:first-page>
                              <sb:last-page>38</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0510">
                     <ce:label>103</ce:label>
                     <sb:reference id="sbref0510">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Frossi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Endonuclease and redox activities of human apurinic/apyrimidinic endonuclease 1 have distinctive and essential functions in IgA class switch recombination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>294</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5198</sb:first-page>
                              <sb:last-page>5207</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>